Ratings Jacobs Solutions Inc. Deutsche Boerse AG

Equities

Z0Y

US46982L1089

Market Closed - Deutsche Boerse AG Other stock markets 02:44:52 28/06/2024 pm IST			5-day change	1st Jan Change
130 ^EUR	+0.78%		-0.76%	+11.11%

27/06	Jacobs Solutions to Support Fujifilm Diosynth Biotechnologies' Expansion in North Carolina	MT
27/06	Jacobs Selected to Support Delivery of $1.2 Billion Expansion of Fujifilm Diosynth Biotechnologies' Large-Scale Biologics Manufacturing Site	CI

Strengths

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company is not the most generous with respect to shareholders' compensation.
Revenue estimates are regularly revised downwards for the current and coming years.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Business Support Services

	1st Jan change	Capi.	ESG Refinitiv
JACOBS SOLUTIONS INC.	+11.11%	17.49B	-
CINTAS CORPORATION	+16.19%	71.05B	B+
RB GLOBAL, INC.	+14.16%	13.96B	B-
BUREAU VERITAS SA	+13.07%	12.57B	A-
INTERTEK GROUP PLC	+12.91%	9.77B	B-
TELEPERFORMANCE SE	-25.53%	6.28B	C
GENPACT LIMITED	-7.26%	5.79B	A-
EXLSERVICE HOLDINGS, INC.	+1.65%	5.09B	A-
EXPONENT, INC.	+8.04%	4.82B	C-
ALS LIMITED	+9.03%	4.53B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes